PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
8935.00 - 9125.00
6347.00 - 10045.00
380.0K / 335.9K (Avg.)
23.15 | 391.09
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
7.00%
Positive revenue growth while 3088.T is negative. John Neff might see a notable competitive edge here.
3.45%
Positive gross profit growth while 3088.T is negative. John Neff would see a clear operational edge over the competitor.
-12.72%
Both companies show negative EBIT growth. Martin Whitman would consider macro or sector-specific headwinds.
-11.49%
Both companies face negative operating income growth. Martin Whitman would suspect broader market or cost hurdles.
44.66%
Positive net income growth while 3088.T is negative. John Neff might see a big relative performance advantage.
44.66%
Positive EPS growth while 3088.T is negative. John Neff might see a significant comparative advantage in per-share earnings dynamics.
44.66%
Positive diluted EPS growth while 3088.T is negative. John Neff might view this as a strong relative advantage in controlling dilution.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
36.07%
10Y revenue/share CAGR at 75-90% of 3088.T's 41.03%. Bill Ackman would press for new markets or product lines to narrow the gap.
-13.38%
Negative 5Y CAGR while 3088.T stands at 21.24%. Joel Greenblatt would push for a turnaround plan or reevaluation of the company’s product line.
32.50%
Positive 3Y CAGR while 3088.T is negative. John Neff might view this as a sharp short-term edge or successful pivot strategy.
-100.00%
Negative 10Y OCF/share CAGR while 3088.T stands at 100.00%. Joel Greenblatt would scrutinize managerial effectiveness and product competitiveness.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
141.27%
Net income/share CAGR at 75-90% of 3088.T's 157.48%. Bill Ackman would press for strategic moves to boost long-term earnings.
37.60%
Below 50% of 3088.T's 76.94%. Michael Burry would worry about a substantial lag vs. the competitor’s profit ramp-up.
124.28%
3Y net income/share CAGR above 1.5x 3088.T's 42.21%. David Dodd would confirm the company’s short-term strategies outmatch the competitor significantly.
132.72%
10Y equity/share CAGR 1.25-1.5x 3088.T's 92.49%. Bruce Berkowitz would see if strong ROE or conservative payout policy fosters faster book value growth.
27.89%
Below 50% of 3088.T's 61.35%. Michael Burry sees a substantially weaker mid-term book value expansion strategy in place.
71.06%
3Y equity/share CAGR above 1.5x 3088.T's 22.74%. David Dodd verifies the company’s short-term capital management far exceeds the competitor’s pace.
-25.00%
Cut dividends over 10 years while 3088.T stands at 26639.54%. Joel Greenblatt suspects a weaker ability to return capital vs. the competitor.
2.27%
Below 50% of 3088.T's 66.67%. Michael Burry worries the firm returns far less capital to shareholders over 5 years.
-25.00%
Negative near-term dividend growth while 3088.T invests at 66.67%. Joel Greenblatt sees a weaker short-term distribution policy unless justified by strategic spending.
-37.14%
Firm’s AR is declining while 3088.T shows 70.75%. Joel Greenblatt sees stronger working capital efficiency if sales hold up.
3.40%
We show growth while 3088.T is shrinking stock. John Neff wonders if the competitor is more disciplined or has weaker demand expectations.
8.47%
Asset growth above 1.5x 3088.T's 0.71%. David Dodd checks if M&A or new capacity expansions are value-accretive vs. competitor's approach.
6.41%
BV/share growth above 1.5x 3088.T's 2.79%. David Dodd confirms if consistent profit retention or fewer write-downs yield faster equity creation.
25.46%
Debt growth of 25.46% while 3088.T is zero. Bruce Berkowitz sees additional leverage that must yield profitable expansions to be worthwhile.
No Data
No Data available this quarter, please select a different quarter.
-42.69%
Both reduce SG&A yoy. Martin Whitman sees a cost war or cyclical slowdown forcing overhead cuts.